Insider Trades
Common-stock transactions that officers, directors and 10% owners of healthcare companies report to the SEC on Form 4, from 2006 to today, newest first.
Insider filings are public records and are not a recommendation.
Results
25+ transactions, newest first
| Date | Insider | Relationship | Company | Transaction | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|---|---|
| Brennan Daniel J. | Director | VERTEX PHARMACEUTICALS INCVRTX | OtherA · Grant or award from the company | 795 | $503.47 | $400,258.65 | 795Direct | Form 4 filed 22 Oct 2026, on sec.gov (opens in a new tab)Filed 22 Oct 2026 | |
| van Grunsven Jasper | EVP, CP and NPPO | VERTEX PHARMACEUTICALS INCVRTX | OtherA · Grant or award from the company | 8,682 | $0.00 | $0 | 8,682Direct | Form 4 filed 10 Sep 2026, on sec.gov (opens in a new tab)Filed 10 Sep 2026 | |
| Ambrose Kristen | SVP & Chief Accounting Officer | VERTEX PHARMACEUTICALS INCVRTX | OtherA · Grant or award from the company | 5,000 | $0.00 | $0 | 11,624Direct | Form 4 filed 1 Sep 2026, on sec.gov (opens in a new tab)Filed 1 Sep 2026 | |
| SACHS BRUCE I | Director | VERTEX PHARMACEUTICALS INCVRTX | OtherG · Gift | 6,000 | $0.00 | $0 | 39,000Direct | Form 4 filed 31 Aug 2026, on sec.gov (opens in a new tab)Filed 31 Aug 2026 | |
| Sachdev Amit | EVP Chief Patient & Ext Af Off | VERTEX PHARMACEUTICALS INCVRTX | OtherA · Grant or award from the company | 8,251 | $0.00 | $0 | 66,512Direct | Form 4 filed 23 Jul 2026, on sec.gov (opens in a new tab)Filed 23 Jul 2026 | |
| Tatsis Ourania | EVP, Chief Reg. & Quality Off. | VERTEX PHARMACEUTICALS INCVRTX | OtherA · Grant or award from the company | 8,251 | $0.00 | $0 | 53,572Direct | Form 4 filed 23 Jul 2026, on sec.gov (opens in a new tab)Filed 23 Jul 2026 | |
| Tatsis Ourania | EVP, Chief Reg. & Quality Off. | VERTEX PHARMACEUTICALS INCVRTX | SellS · Open-market or private sale | 1,500 | $524.99 | $787,485 | 45,321Direct | Form 4 filed 7 Jul 2026, on sec.gov (opens in a new tab)Filed 7 Jul 2026 | |
| McKechnie Duncan | EVP, Chief Commercial Officer | VERTEX PHARMACEUTICALS INCVRTX | SellS · Open-market or private sale | 1,541 | $519.00 | $799,779 | 11,001Direct | Form 4 filed 7 Jul 2026, on sec.gov (opens in a new tab)Filed 7 Jul 2026 | |
| Liu Joy | EVP and Chief Legal Officer | VERTEX PHARMACEUTICALS INCVRTX | SellS · Open-market or private sale | 828 | $502.71 | $416,243.88 | 19,131Direct | Form 4 filed 6 Jul 2026, on sec.gov (opens in a new tab)Filed 6 Jul 2026 | |
| Bozic Carmen | EVP and CMO | VERTEX PHARMACEUTICALS INCVRTX | SellS · Open-market or private sale | 596 | $482.50 | $287,570 | 15,337Direct | Form 4 filed 30 Jun 2026, on sec.gov (opens in a new tab)Filed 30 Jun 2026 | |
| Bozic Carmen | EVP and CMO | VERTEX PHARMACEUTICALS INCVRTX | SellS · Open-market or private sale | 1,020 | $462.17 | $471,413.40 | 15,933Direct | Form 4 filed 23 Jun 2026, on sec.gov (opens in a new tab)Filed 23 Jun 2026 | |
| Bozic Carmen | EVP and CMO | VERTEX PHARMACEUTICALS INCVRTX | SellS · Open-market or private sale | 4,062 | $450.00 | $1,827,900 | 16,953Direct | Form 4 filed 17 Jun 2026, on sec.gov (opens in a new tab)Filed 17 Jun 2026 | |
| Bozic Carmen | EVP and CMO | VERTEX PHARMACEUTICALS INCVRTX | SellS · Open-market or private sale | 1,745 | $450.00 | $785,250 | 21,015Direct | Form 4 filed 9 Jun 2026, on sec.gov (opens in a new tab)Filed 9 Jun 2026 | |
| Liu Joy | EVP and Chief Legal Officer | VERTEX PHARMACEUTICALS INCVRTX | SellS · Open-market or private sale | 828 | $439.91 | $364,245.48 | 19,959Direct | Form 4 filed 3 Jun 2026, on sec.gov (opens in a new tab)Filed 3 Jun 2026 | |
| Bozic Carmen | EVP and CMO | VERTEX PHARMACEUTICALS INCVRTX | SellS · Open-market or private sale | 1,974 | $450.00 | $888,300 | 22,760Direct | Form 4 filed 2 Jun 2026, on sec.gov (opens in a new tab)Filed 2 Jun 2026 | |
| Bozic Carmen | EVP and CMO | VERTEX PHARMACEUTICALS INCVRTX | SellS · Open-market or private sale | 1,354 | $453.45 | $613,971.30 | 24,734Direct | Form 4 filed 19 May 2026, on sec.gov (opens in a new tab)Filed 19 May 2026 | |
| Bunnage Mark E. | EVP, Chief Scientific Officer | VERTEX PHARMACEUTICALS INCVRTX | SellS · Open-market or private sale | 33 | $453.45 | $14,963.85 | 7,284Direct | Form 4 filed 19 May 2026, on sec.gov (opens in a new tab)Filed 19 May 2026 | |
| Bozic Carmen | EVP and CMO | VERTEX PHARMACEUTICALS INCVRTX | SellS · Open-market or private sale | 6,988 | $450.00 | $3,144,600 | 26,088Direct | Form 4 filed 14 May 2026, on sec.gov (opens in a new tab)Filed 14 May 2026 | |
| Bhatia Sangeeta N. | Director | VERTEX PHARMACEUTICALS INCVRTX | SellS · Open-market or private sale | 318 | $423.73 | $134,746.14 | 4,924Direct | Form 4 filed 5 May 2026, on sec.gov (opens in a new tab)Filed 5 May 2026 | |
| Thornberry Nancy | Director | VERTEX PHARMACEUTICALS INCVRTX | OtherD · Sale or transfer back to the company | 398 | Not reported | No price reported | 2,109Direct | Form 4 filed 5 May 2026, on sec.gov (opens in a new tab)Filed 5 May 2026 | |
| Thornberry Nancy | Director | VERTEX PHARMACEUTICALS INCVRTX | OtherA · Grant or award from the company | 472 | $0.00 | $0 | 2,507Direct | Form 4 filed 5 May 2026, on sec.gov (opens in a new tab)Filed 5 May 2026 | |
| Bhatia Sangeeta N. | Director | VERTEX PHARMACEUTICALS INCVRTX | OtherA · Grant or award from the company | 943 | $0.00 | $0 | 5,242Direct | Form 4 filed 5 May 2026, on sec.gov (opens in a new tab)Filed 5 May 2026 | |
| Liu Joy | EVP and Chief Legal Officer | VERTEX PHARMACEUTICALS INCVRTX | SellS · Open-market or private sale | 1,104 | $425.02 | $469,222.08 | 20,729Direct | Form 4 filed 5 May 2026, on sec.gov (opens in a new tab)Filed 5 May 2026 | |
| Garber Alan M | Director | VERTEX PHARMACEUTICALS INCVRTX | OtherA · Grant or award from the company | 472 | $0.00 | $0 | 7,344Direct | Form 4 filed 5 May 2026, on sec.gov (opens in a new tab)Filed 5 May 2026 | |
| Schneider Jennifer | Director | VERTEX PHARMACEUTICALS INCVRTX | OtherD · Sale or transfer back to the company | 796 | Not reported | No price reported | 1,394Direct | Form 4 filed 5 May 2026, on sec.gov (opens in a new tab)Filed 5 May 2026 |
Source: SEC EDGAR Form 4 filings and the SEC Insider Transactions Data Sets (2006 onward). Each row links to its Form 4 filing. Values are shares times the reported price. Nothing here is investment advice.